Sancilio
Riviera Beach, US · 1 known investors
Find your way into Sancilio
42 people in our graph share verified history with the Sancilio team — schools, employers, funds. One of them is your warm intro.
Christian Jaagunlockedknows Frederick Sancilio · together at Rutgers University–Newark
×9knows the team · via Rutgers University–Newark
knows the team · via Burroughs Wellcome Company
knows the team · via Florida Atlantic University
Sancilio & Company provides guidance and regulatory support to early-stage biopharmaceutical entrepreneurs on compliance, manufacturing, and funding strategy. Through its subsidiary Clearway Global, the firm offers a network of FDA-regulated services including drug manufacturing, formulation development, clinical trials, and regulatory submissions.
Founders & leadership
FS
Frederick SancilioinFounderFrederick Sancilio is Principal Owner and Operating Partner of Sancilio & Company, Inc., which provides regulatory guidance and manufacturing support to early-stage biopharmaceutical companies, and President of its consulting subsidiary Clearway Global. He has founded multiple healthcare companies including aaiPharma (now Alcami), Aesgen, and Endeavor Pharmaceuticals, held CEO and board positions at public and private biopharmaceutical firms, and serves as Research Professor at Florida Atlantic University.
DG
Daren GrahamExecutive
AF
Andrew FolmerExecutive
SP
Stephen PorterExecutive
Board
DL
Dennis LangerBoard director
PG
Patrick GrayBoard director
AD
Alan DuntonBoard director
RJ
Roderick JacksonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22M disclosed across 2 rounds · 2012–2014
▶$20MraisedJul 2014 · 9 investors · PharmaceuticalsRule 506(b)
▶$20MraisedJul 2014 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roderick JacksonDirector
- Dennis LangerDirector
- C. Chad HarrellExecutive Officer
- Ted StoverExecutive Officer
- Alan DuntonDirector
- Frederick SancilioExecutive Officer, Director
- Martin ZeigerDirector
- Patrick GrayDirector
- Kelly PerkinsDirector
- Thorsteinsson ThorsteinnExecutive Officer
- Carla CoxExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- Minimum investment
- $1
- Sales commissions
- $1M
- Placement agents
- Noble Financial Capital Markets
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2012 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedMar 2012 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis LangerDirector
- Daren GrahamExecutive Officer
- Frederick SancilioExecutive Officer, Director
- Andrew FolmerExecutive Officer
- Patrick GrayDirector
- Alan DuntonDirector
- Stephen PorterExecutive Officer
- Roderick JacksonDirector
- Offering amount
- $4M
- Amount sold
- $2M
- Minimum investment
- $1
- Proceeds to insiders
- $50K
- First sale
- Feb 2012
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Sancilio do?
- Sancilio & Company provides guidance and regulatory support to early-stage biopharmaceutical entrepreneurs on compliance, manufacturing, and funding strategy. Through its subsidiary Clearway Global, the firm offers a network of FDA-regulated services including drug manufacturing, formulation development, clinical trials, and regulatory submissions.
- Who founded Sancilio?
- Sancilio was founded by Frederick Sancilio.
- Who are Sancilio's investors?
- Sancilio's investors include Signet Healthcare Partners.
- How much funding has Sancilio raised?
- Sancilio has disclosed $22M raised across 2 rounds.
- Where is Sancilio headquartered?
- Sancilio is headquartered in Riviera Beach, US.